Up to a third of patients taking methotrexate – a common treatment for immune mediated inflammatory conditions such as rheumatoid arthritis and psoriasis/psoriatic arthritis – failed to achieve an adequate immune response to mRNA COVID-19 vaccines in a small study accepted for publication in the journal Annals of the Rheumatic Diseases.
Hydroxychloroquine + Azithromycin therapy at a higher dose improved survival by nearly 200% in ventilated COVID patients
However, a fascinating new study posted to the medRxiv* preprint server suggests that such disappointment may have been both premature and unwarranted, based on a re-analysis of over 250 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic.
One-quarter of people who take the drug methotrexate for common immune system disorders — from rheumatoid arthritis to multiple sclerosis — mount a weaker immune response to a COVID-19 vaccine, a new study shows.
The day Dr. Elizabeth Dawson was diagnosed with covid-19 in October, she awoke feeling as if she had a bad hangover. Four months later she tested negative for the virus, but her symptoms have only worsened.